Table 2.
Country | Entity | n | LMP1 Variant | Reference | |
---|---|---|---|---|---|
30 bp del | WT | ||||
Mexico | ENKTCL | 42 cases | 10 (23.8%) | 32 (76.2%) | [82] |
Peru | ENKTCL | 27 cases | 0 | 12 (100%) | [78] |
Argentina | ENKTCL | 12 cases | 5 (41.7%) | 7 (58.3%) | [82] |
China | ENKTCL | 13 cases | 10 (76.9%) | 3 (23.1%) | [120] |
China | ENKTCL | 23 cases | 21 (91.3%) | 2 (8.7%) | [84] |
Mexico | ENKTCL | 23 cases | 6 (26%) | 17 (73.9%) | [6] |
Malaysia | PTCL | 9 cases | 9 (100%) | 0 | [86] |
Denmark | PTCL | 18 cases | 11 (61.1%) | 7 (38.9%) | [86] |
ENKTCL: extranodal natural killer T cell lymphoma; 30 bp del: 30 base pair deletion variant; WT: wild type; PTCL: peripheral T cell lymphoma. In addition to the LMP1 del variant, the loss of the restriction site Xho I in LMP1 has been shown in nasopharyngeal carcinoma in Asian pop-ulation [97,121,122,123].